ASCO Annual Meeting: Genitourinary | Conference

Tanya Dorff, MD, Discusses Next Steps With CAR T-Cell Therapy in Prostate Cancer
September 21, 2022

Tanya Dorff, MD, spoke about how CAR T-cell therapy could be a potential new addition to the prostate cancer treatment paradigm based on data from ongoing studies.

Tanya Dorff, MD, Speaks to the Development of CAR T-Cell Therapy in Prostate Cancer
September 17, 2022

At 2022 ASCO, Tanya Dorff, MD, reviewed the use of CAR T cells in the treatment of prostate cancer.

Phillip H. Kuo, MD, PhD, Assesses Use of 177Lu-PSMA-617 in a Multidisciplinary Setting for Pretreated mCRPC
September 06, 2022

Phillip H. Kuo, MD, PhD, spoke about incorporating prostate-specific membrane antigen–PET imaging into multidisciplinary care for patients with metastatic castration-resistant prostate cancer.

Phillip H. Kuo, MD, PhD, Evaluates Future Research Surrounding PSMA-PET Parameters and Response to 177Lu-PSMA-617 in mCRPC
September 02, 2022

Phillip H. Kuo, MD, PhD, spoke about the future of theragnostic imaging in patients with metastatic castration-resistant prostate cancer.

Phillip H. Kuo, MD, PhD, Examines Utility of PSMA-PET Parameters to Predict Response to 177Lu-PSMA-617 in mCRPC
August 29, 2022

Phillip H. Kuo, MD, PhD, spoke about how prostate-specific membrane antigen PET scan testing affected outcomes in patients with metastatic castration-resistant prostate cancer.

Ian D. Davis, MBBS, PhD, Reviews Interesting Data From TheraP Trial of 177Lu-PSMA-617 in mCRPC at 2022 ASCO
August 29, 2022

Ian D. Davis, MBBS, PhD, spoke about the TheraP study which evaluated 177Lu-PSMA-617 vs cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Phillip H. Kuo, MD, PhD, Reviews Rationale of Phase 3 VISION Trial of 177Lu-PSMA-617 in mCRPC
August 24, 2022

Phillip H. Kuo, MD, PhD, spoke about the use of theragnostic treatment and imaging for patients with metastatic castration-resistant prostate cancer.

Ian D. Davis, MBBS, PhD, Dives Into Subgroup Data from the ENZAMET Trial of Enzalutamide in mHSPC at 2022 ASCO
August 13, 2022

Ian D. Davis, MBBS, PhD, spoke about the subgroup analysis of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.

Andrew J. Armstrong, MD, Details PSMA-PET Scan Parameters Indicating Better Survival Outcomes With 177Lu-PSMA-617 in mCRPC
August 04, 2022

Data from a substudy of the phase 3 VISION trial presented at 2022 ASCO Annual Meeting showed that higher standard mean uptake value by PSMA-PET is strongly associated with outcomes for patients with metastatic castration-resistant prostate cancer.

Ian D. Davis, MBBS, PhD, Details Rationale and Topline Survival Results of the ENZAMET Trial Examining Enzalutamide in mHSPC at 2022 ASCO
August 01, 2022

Ian D. Davis, MBBS, PhD, spoke about updated survival results of the ENZAMET trial which analyzed enzalutamide in metastatic hormone-sensitive prostate cancer.